

Lindsay N Carpp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7340328/publications.pdf>

Version: 2024-02-01

47
papers

2,985
citations

331670

21
h-index

243625

44
g-index

58
all docs

58
docs citations

58
times ranked

5057
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Neutralizing Antibodies as a Correlate of Instantaneous Risk of Hospitalized Dengue in Placebo Recipients of Dengue Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2022, 225, 332-340.	4.0	1
2	Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	3.3	6
3	Single-cell immunology of SARS-CoV-2 infection. <i>Nature Biotechnology</i> , 2022, 40, 30-41.	17.5	78
4	Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study. <i>ELife</i> , 2022, 11, .	6.0	4
5	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	12.6	788
6	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020-March 2021) Using a Statistical Learning Strategy. <i>Viruses</i> , 2022, 14, 9.	3.3	10
7	Analysis of the HIV Vaccine Trials Network 702 Phase 2b HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. <i>Journal of Infectious Diseases</i> , 2022, 226, 246-257.	4.0	11
8	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	3.9	86
9	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , 2021, 64, 103203.	6.1	14
10	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , 2021, 17, e1009363.	4.7	19
11	Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. <i>Frontiers in Big Data</i> , 2021, 4, 672460.	2.9	8
12	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	3.9	15
13	Early Pro-Inflammatory Signal and T-Cell Activation Associate With Vaccine-Induced Anti-Vaccinia Protective Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 737487.	4.8	2
14	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	12.6	145
15	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. <i>Scientific Reports</i> , 2021, 11, 23921.	3.3	44
16	Orchestrating single-cell analysis with Bioconductor. <i>Nature Methods</i> , 2020, 17, 137-145.	19.0	488
17	Microneutralization assay titer correlates analysis in two phase 3 trials of the CYD-TDV tetravalent dengue vaccine in Asia and Latin America. <i>PLoS ONE</i> , 2020, 15, e0234236.	2.5	9
18	Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 434-439.	2.1	3

#	ARTICLE	IF	CITATIONS
19	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16
20	Title is missing!. , 2020, 15, e0234236.		0
21	Title is missing!. , 2020, 15, e0234236.		0
22	Title is missing!. , 2020, 15, e0234236.		0
23	Title is missing!. , 2020, 15, e0234236.		0
24	Combining Viral Genetics and Statistical Modeling to Improve HIV-1 Time-of-Infection Estimation towards Enhanced Vaccine Efficacy Assessment. <i>Viruses</i> , 2019, 11, 607.	3.3	12
25	Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. <i>Journal of Virology</i> , 2019, 93, .	3.4	26
26	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019, 26, 336-346.e3.	11.0	88
27	HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. <i>BMC Infectious Diseases</i> , 2019, 19, 453.	2.9	23
28	Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. <i>PLoS Computational Biology</i> , 2019, 15, e1006952.	3.2	25
29	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2741.	4.8	25
30	Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 101, 164-179.	1.4	9
31	Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. <i>Journal of Infectious Diseases</i> , 2018, 217, 1280-1288.	4.0	32
32	Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America. <i>Journal of Infectious Diseases</i> , 2018, 217, 742-753.	4.0	80
33	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2116-2127.	3.3	17
34	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 645-656.	1.1	23
35	Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8378-E8387.	7.1	57
36	Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. <i>Tuberculosis</i> , 2018, 109, 61-68.	1.9	28

#	ARTICLE	IF	CITATIONS
37	A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine. <i>Journal of Immunology</i> , 2017, 199, 1476-1489.	0.8	40
38	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017, 12, e0176428.	2.5	12
39	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	2.5	27
40	Quantitative Proteomic Analysis of Host-virus Interactions Reveals a Role for Golgi Brefeldin A Resistance Factor 1 (GBF1) in Dengue Infection. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2836-2854.	3.8	49
41	Homotypic Vacuole Fusion in Yeast Requires Organelle Acidification and Not the V-ATPase Membrane Domain. <i>Developmental Cell</i> , 2013, 27, 462-468.	7.0	52
42	The Sec1/Munc18 Protein Vps45 Regulates Cellular Levels of Its SNARE Binding Partners Tlg2 and Snc2 in <i>Saccharomyces cerevisiae</i> . <i>PLoS ONE</i> , 2012, 7, e49628.	2.5	13
43	Interaction between the yellow fever virus nonstructural protein NS3 and the host protein Alix contributes to the release of infectious particles. <i>Microbes and Infection</i> , 2011, 13, 85-95.	1.9	46
44	Functional homology of mammalian syntaxin 16 and yeast Tlg2p reveals a conserved regulatory mechanism. <i>Journal of Cell Science</i> , 2009, 122, 2292-2299.	2.0	25
45	Cellular levels of the syntaxin Tlg2p are regulated by a single mode of binding to Vps45p. <i>Biochemical and Biophysical Research Communications</i> , 2007, 363, 857-860.	2.1	7
46	The Sec1p/Munc18 protein Vps45p binds its cognate SNARE proteins via two distinct modes. <i>Journal of Cell Biology</i> , 2006, 173, 927-936.	5.2	96
47	A role for the actin cytoskeleton in cell death and aging in yeast. <i>Journal of Cell Biology</i> , 2004, 164, 803-809.	5.2	262